Bharat Biotech and Bilthoven Biologicals Partner To Produce OPV Vaccine

Bharat Biotech, a leading vaccines & bio-therapeutics manufacturer, declared a partnership to fortify the creation of oral polio immunizations and supply security (OPV). The agreement has been endorsed between BBIL and BBio wherein BBIL will secure medication substances to develop oral polio immunizations in India and worldwide.   

Through this cooperation, both firms will mutually acquire the administrative endorsements and licenses expected to manufacture and produce OPVs in India for worldwide supplies from drug substances made in the Netherlands at Bilthoven Biologicals.

Adar Poonawalla, CEO, Serum Institute of India, said, “We are delighted to join forces with Bharat Biotech to reinforce the global supply of polio vaccines. Our vision is to eradicate Polio worldwide, taking a crucial step towards reducing the impact of this deadly disease on vulnerable populations.”  

Dr Krishna Ella, executive chairman of Bharat Biotech, said, “Oral polio vaccines have been an integral part of the Government of India’s Universal Immunisation Programme (UIP) for several decades, with Bharat Biotech being one of the largest suppliers to immunisation programmes across the world. This collaboration between BBIL and BBio exemplifies cooperation between vaccine companies, ensuring a secure supply of oral polio vaccines and fortifies the nation’s mission to eradicate polio.”  

As we approach the basic period of worldwide polio destruction, this cooperation will uphold the work to make a polio-liberated world, he added.